<p>根据 Briefing.com 的报道，投资分析师在周四发布的研究报告中，将 Zentalis Pharmaceuticals（纳斯达克股票代码：ZNTL）的评级从 “买入” 调降至 “中性”。他们目前将该股票的目标价格定为 5.00 美元，低于之前的 28.00 美元。UBS 集团的目标价格表明，相较于公司之前的收盘价，有 20.77% 的潜在上涨空间。</p>
<p>其他股票分析师最近也发布了关于该公司的研究报告。富国银行公司将 Zentalis Pharmaceuticals 的评级从 “超重” 调降至 “持平”，并将其目标价格从 29.00 美元降至 9.00 美元。Stifel Nicolaus 将 Zentalis Pharmaceuticals 的目标价格从 32.00 美元降至 10.00 美元，并为该公司设定了 “买入” 评级。摩根士丹利重新确认了 “持平” 评级，并将 Zentalis Pharmaceuticals 的目标股价设定为 8.00 美元（之前为 38.00 美元）。HC Wainwright 将 Zentalis Pharmaceuticals 的目标股价从 40.00 美元降至 20.00 美元，并为该公司设定了 “买入” 评级。最后，Wedbush 将 Zentalis Pharmaceuticals 的股票评级从 “中性” 调降至 “表现不佳”，并将其目标价格从 15.00 美元降至 4.00 美元。一位研究分析师给予该股票卖出评级，六位持有评级，三位给予买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价格为 11.33 美元。</p>
<p><strong>阅读我们对 ZNTL 的最新分析</strong></p>
<h2>Zentalis Pharmaceuticals 股价下跌 50.7%</h2>
<p>周四，Zentalis Pharmaceuticals 股票开盘价为 4.14 美元。该公司市值为 2.9406 亿美元，市盈率为-1.24，贝塔系数为 1.83。Zentalis Pharmaceuticals 的 52 周最低价为 3.93 美元，最高价为 30.53 美元。该公司的 50 天简单移动平均线为 11.53 美元，200 天简单移动平均线为 13.08 美元。</p>
<p>Zentalis Pharmaceuticals（纳斯达克股票代码：ZNTL）于 5 月 7 日星期二公布了其季度收益结果。该公司季度每股盈利为 0.14 美元，高于预期的（0.77）美元。该季度公司营收为 4056 万美元，超过分析师预期的 3500 万美元。去年同期，该公司每股亏损为（1.07）美元。作为一组，股票分析师预计 Zentalis Pharmaceuticals 今年将每股亏损 2.72 美元。</p>
<h2>Zentalis Pharmaceuticals 内部交易活动</h2>
<p>据相关消息，首席财务官 Cam Gallagher 于 5 月 31 日星期五进行了一笔交易，卖出了公司股票的 9597 股。这些股票的平均价格为 11.98 美元，总交易额为 114972.06 美元。交易完成后，首席财务官在公司拥有 633680 股股票，价值 7591486.40 美元。该交易已在提交给证券交易委员会的文件中披露，可以通过此超链接访问。此外，Zentalis Pharmaceuticals 的内部人员 Diana Hausman 于 5 月 9 日星期四出售了 3356 股公司股票。股票的平均价格为 12.62 美元，总价值为 42352.72 美元。交易完成后，该内部人员现在直接持有公司 373876 股股票，价值 4718315.12 美元。该交易已在提交给证券交易委员会的文件中披露，可在 SEC 网站上查看。此外，首席财务官 Cam Gallagher 于 5 月 31 日星期五进行了一笔交易，卖出了 9597 股公司股票。股票的平均价格为 11.98 美元，总价值为 114972.06 美元。交易完成后，首席财务官现在直接持有公司 633680 股股票，价值 7591486.40 美元。此次交易的披露信息可在此处找到。目前有 6.10% 的股票由公司内部人员持有。</p>
<h2>机构投资者对 Zentalis Pharmaceuticals 的看法</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了他们在该公司的持股。Quest Partners LLC 在第四季度购入了 Zentalis Pharmaceuticals 的新头寸，价值约 38000 美元。Tower Research Capital LLC TRC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 252.3%，现在拥有 3615 股公司股票，价值 55000 美元，比上季度增加了 2589 股。Exchange Traded Concepts LLC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 34.0%，现在拥有 5989 股公司股票，价值 91000 美元，比上季度增加了 1519 股。中国通用资产管理有限公司在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 352.6%，现在拥有 8188 股公司股票，价值 124000 美元，比上季度增加了 6379 股。最后，OneAscent Financial Services LLC 在第四季度购入了 Zentalis Pharmaceuticals 的新头寸，价值 156000 美元。</p>
<h2>关于 Zentalis Pharmaceuticals（获取免费报告）</h2>
<p>Zentalis Pharmaceuticals, Inc.是一家临床阶段生物制药公司，专注于发现和开发用于治疗各种癌症的小分子治疗药物。其产品候选包括 ZN-c3，一种 WEE1 抑制剂，用于治疗晚期实体肿瘤和血液恶性肿瘤；目前正在进行 II 期临床试验，作为子宫浆液性癌治疗的单药疗法；在 Cyclin E1 驱动的高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌中进行 II 期临床试验；与 PARPi 联合用于铂类耐药性卵巢癌的 I/II 期临床试验；与化疗联合用于铂类耐药性卵巢癌、腹膜或输卵管癌的 Ib 期临床试验；与化疗联合用于复发或难治性骨肉瘤的 I/II 期临床试验；与 encorafenib 和 cetuximab 联合用于突变转移性结直肠癌的 I/II 期临床试验；以及与化疗联合用于胰腺癌的 I/II 期临床试验。</p>
<h2>更多阅读</h2>
<ul>
<li>五只我们比 Zentalis Pharmaceuticals 更喜欢的股票</li>
<li>投资高市盈率成长股</li>
<li>Signet Jewelers 股票在盈利下滑后有望反弹</li>
<li>逐步购买便宜股票的方法</li>
<li>Airship AI 获得新合同：股价飙升 16%，还有更多</li>
<li>银行股 - 最值得投资的银行股</li>
<li>Restoration Hardware 股票：盈利下滑后是否值得购买？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 拜登将推出 “FedNOW” [立即转移您的资金]（来自 Priority Gold）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz"/></p>
<h2>现在是否值得投资$1,000 在 Zentalis Pharmaceuticals？</h2>
<p>在考虑投资 Zentalis Pharmaceuticals 之前，您需要听到这个消息。</p>
<p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Zentalis Pharmaceuticals 不在其中。</p>
<p>虽然 Zentalis Pharmaceuticals 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ZNTL

<p>Zentalis Pharmaceuticals（纳斯达克股票代码：ZNTL）已经被瑞银集团从 “买入” 评级下调为 “中性” 评级。该公司的价格目标也从 28.00 美元降低至 5.00 美元。其他分析师也发布了下调评级并降低了该公司的价格目标。该股周四开盘价为 4.14 美元，市场普遍看法为 “持有”，共识价格目标为 11.33 美元。Zentalis Pharmaceuticals 报告了季度超出预期的盈利结果，但其股价一直在下跌</p>

<p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was downgraded by investment analysts at UBS Group from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research report issued on Thursday, Briefing.com reports. They presently have a $5.00 price objective on the stock, down from their previous price objective of $28.00. UBS Group's price target indicates a potential upside of 20.77% from the company's previous close.</p>
<div class="lb-trans"><p>根据 Briefing.com 的报道，投资分析师在周四发布的研究报告中，将 Zentalis Pharmaceuticals（纳斯达克股票代码：ZNTL）的评级从 “买入” 调降至 “中性”。他们目前将该股票的目标价格定为 5.00 美元，低于之前的 28.00 美元。UBS 集团的目标价格表明，相较于公司之前的收盘价，有 20.77% 的潜在上涨空间。</p>
</div><p>Other equities analysts have also recently issued research reports about the company. Wells Fargo &amp; Company cut Zentalis Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and decreased their price objective for the company from $29.00 to $9.00 in a research note on Tuesday. Stifel Nicolaus lowered their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Morgan Stanley reissued an &#34;equal weight&#34; rating and set a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday. HC Wainwright lowered their price target on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday. Finally, Wedbush cut shares of Zentalis Pharmaceuticals from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and cut their price objective for the stock from $15.00 to $4.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $11.33.</p>
<div class="lb-trans"><p>其他股票分析师最近也发布了关于该公司的研究报告。富国银行公司将 Zentalis Pharmaceuticals 的评级从 “超重” 调降至 “持平”，并将其目标价格从 29.00 美元降至 9.00 美元。Stifel Nicolaus 将 Zentalis Pharmaceuticals 的目标价格从 32.00 美元降至 10.00 美元，并为该公司设定了 “买入” 评级。摩根士丹利重新确认了 “持平” 评级，并将 Zentalis Pharmaceuticals 的目标股价设定为 8.00 美元（之前为 38.00 美元）。HC Wainwright 将 Zentalis Pharmaceuticals 的目标股价从 40.00 美元降至 20.00 美元，并为该公司设定了 “买入” 评级。最后，Wedbush 将 Zentalis Pharmaceuticals 的股票评级从 “中性” 调降至 “表现不佳”，并将其目标价格从 15.00 美元降至 4.00 美元。一位研究分析师给予该股票卖出评级，六位持有评级，三位给予买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价格为 11.33 美元。</p>
</div><p><strong>Read Our Latest Analysis on ZNTL</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 ZNTL 的最新分析</strong></p>
</div><h2>Zentalis Pharmaceuticals Stock Down 50.7 %</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 股价下跌 50.7%</h2>
</div><p>Shares of Zentalis Pharmaceuticals stock opened at $4.14 on Thursday. The firm has a market cap of $294.06 million, a PE ratio of -1.24 and a beta of 1.83. Zentalis Pharmaceuticals has a 52 week low of $3.93 and a 52 week high of $30.53. The business's fifty day simple moving average is $11.53 and its 200-day simple moving average is $13.08.</p>
<div class="lb-trans"><p>周四，Zentalis Pharmaceuticals 股票开盘价为 4.14 美元。该公司市值为 2.9406 亿美元，市盈率为-1.24，贝塔系数为 1.83。Zentalis Pharmaceuticals 的 52 周最低价为 3.93 美元，最高价为 30.53 美元。该公司的 50 天简单移动平均线为 11.53 美元，200 天简单移动平均线为 13.08 美元。</p>
</div><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same quarter last year, the business posted ($1.07) EPS. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（纳斯达克股票代码：ZNTL）于 5 月 7 日星期二公布了其季度收益结果。该公司季度每股盈利为 0.14 美元，高于预期的（0.77）美元。该季度公司营收为 4056 万美元，超过分析师预期的 3500 万美元。去年同期，该公司每股亏损为（1.07）美元。作为一组，股票分析师预计 Zentalis Pharmaceuticals 今年将每股亏损 2.72 美元。</p>
</div><h2>Insider Activity at Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 内部交易活动</h2>
</div><p>In related news, CFO Cam Gallagher sold 9,597 shares of the firm's stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the firm's stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company's stock, valued at $4,718,315.12. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Cam Gallagher sold 9,597 shares of the business's stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>据相关消息，首席财务官 Cam Gallagher 于 5 月 31 日星期五进行了一笔交易，卖出了公司股票的 9597 股。这些股票的平均价格为 11.98 美元，总交易额为 114972.06 美元。交易完成后，首席财务官在公司拥有 633680 股股票，价值 7591486.40 美元。该交易已在提交给证券交易委员会的文件中披露，可以通过此超链接访问。此外，Zentalis Pharmaceuticals 的内部人员 Diana Hausman 于 5 月 9 日星期四出售了 3356 股公司股票。股票的平均价格为 12.62 美元，总价值为 42352.72 美元。交易完成后，该内部人员现在直接持有公司 373876 股股票，价值 4718315.12 美元。该交易已在提交给证券交易委员会的文件中披露，可在 SEC 网站上查看。此外，首席财务官 Cam Gallagher 于 5 月 31 日星期五进行了一笔交易，卖出了 9597 股公司股票。股票的平均价格为 11.98 美元，总价值为 114972.06 美元。交易完成后，首席财务官现在直接持有公司 633680 股股票，价值 7591486.40 美元。此次交易的披露信息可在此处找到。目前有 6.10% 的股票由公司内部人员持有。</p>
</div><h2>Institutional Investors Weigh In On Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Zentalis Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC raised its position in shares of Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company's stock valued at $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company's stock valued at $91,000 after buying an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company's stock worth $124,000 after buying an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $156,000.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了他们在该公司的持股。Quest Partners LLC 在第四季度购入了 Zentalis Pharmaceuticals 的新头寸，价值约 38000 美元。Tower Research Capital LLC TRC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 252.3%，现在拥有 3615 股公司股票，价值 55000 美元，比上季度增加了 2589 股。Exchange Traded Concepts LLC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 34.0%，现在拥有 5989 股公司股票，价值 91000 美元，比上季度增加了 1519 股。中国通用资产管理有限公司在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 352.6%，现在拥有 8188 股公司股票，价值 124000 美元，比上季度增加了 6379 股。最后，OneAscent Financial Services LLC 在第四季度购入了 Zentalis Pharmaceuticals 的新头寸，价值 156000 美元。</p>
</div><h2>About Zentalis Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Zentalis Pharmaceuticals（获取免费报告）</h2>
</div><p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.是一家临床阶段生物制药公司，专注于发现和开发用于治疗各种癌症的小分子治疗药物。其产品候选包括 ZN-c3，一种 WEE1 抑制剂，用于治疗晚期实体肿瘤和血液恶性肿瘤；目前正在进行 II 期临床试验，作为子宫浆液性癌治疗的单药疗法；在 Cyclin E1 驱动的高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌中进行 II 期临床试验；与 PARPi 联合用于铂类耐药性卵巢癌的 I/II 期临床试验；与化疗联合用于铂类耐药性卵巢癌、腹膜或输卵管癌的 Ib 期临床试验；与化疗联合用于复发或难治性骨肉瘤的 I/II 期临床试验；与 encorafenib 和 cetuximab 联合用于突变转移性结直肠癌的 I/II 期临床试验；以及与化疗联合用于胰腺癌的 I/II 期临床试验。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Zentalis Pharmaceuticals</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Signet Jewelers Stock Poised for Rebound After Earnings Drop</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>Airship AI Lands New Contract: Stock Soars 16% and More to Come</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Restoration Hardware Stock: Should You Buy After Earnings Drop?</li>
</ul>
<div class="lb-trans"><h2>更多阅读</h2>
<ul>
<li>五只我们比 Zentalis Pharmaceuticals 更喜欢的股票</li>
<li>投资高市盈率成长股</li>
<li>Signet Jewelers 股票在盈利下滑后有望反弹</li>
<li>逐步购买便宜股票的方法</li>
<li>Airship AI 获得新合同：股价飙升 16%，还有更多</li>
<li>银行股 - 最值得投资的银行股</li>
<li>Restoration Hardware 股票：盈利下滑后是否值得购买？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ZNTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold)(Ad)</p>
<div class="lb-trans"><p>→ 拜登将推出 “FedNOW” [立即转移您的资金]（来自 Priority Gold）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8043&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Zentalis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Zentalis Pharmaceuticals？</h2>
</div><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Zentalis Pharmaceuticals 之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Zentalis Pharmaceuticals 不在其中。</p>
</div><p>While Zentalis Pharmaceuticals currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zentalis Pharmaceuticals 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Zentalis Pharmaceuticals（纳斯达克代码：ZNTL）在瑞银集团的评级被降为 “中性”